

UNCLASSIFIED

FY 07 Outlook

September 27, 2006

PRESENTED TO:

NDIA Breakfast

STEPHEN V. REEVES
Major General, USA
Joint Program Executive Officer
for Chemical and Biological Defense
(703) 681-9600





FY 2007 CBDP Appropriations

	Budget Request (\$M)	HAC (\$M)	SAC (\$M)	Conference Report (\$M)
CBDP Procurement Total	\$ 506.4	\$ 512.4	\$ 520.4	\$ 519.0
+/- PBR		+ \$ 5.9	+ \$ 14.0	+\$ 12.6
CBDP RDT&E Total	\$ 959.1	\$ 1,037.4	\$ 893.3	\$ 984.9
+/- PBR		+ \$ 78.3	- \$ 65.8	+\$ 25.8
CBDP Program Total	\$ 1,465.5	\$ 1,549.8	\$ 1,413.7	\$ 1,503.9
+/- PBR		+ \$ 84.3	- \$ 51.8	+\$ 38.4



FY 2007 CBDP RDT&E Appropriations

Technology Base – Final Appropriation Marks

BA1: Basic Research (Request: \$99.2M/ Conference: \$104.7M) (+\$5.5M)

- Transformational Medical Technology Initiative (-\$15.0M)
- + 10 Unrequested Adds +\$20.5M

BA2: Applied Research (Request: \$280.4M/ Conference: \$259.9M) (-\$20.5M)

- Transformational Medical Technology Initiative (-\$55.0M)
- +18 Unrequested Adds +\$34.5M

BA3: Advanced Technology Development (Request: \$207.1M/Conference: \$236.7M) (+\$29.6M)

- Transformational Medical Technology Initiative (-\$20.0M)
- +28 Unrequested Adds +\$49.6M



FY 2007 CBDP RDT&E Appropriations

Advanced Development – Final Appropriation Marks

BA 4: Advanced Component Development & Prototypes/ Demonstration and Validation (Request: \$73.1M/ Conference: \$80.7M) (+\$7.6M)

- Seven (7) adds for a total of \$9.6M
- Chemical and Biological Networked Early Warning System (-\$2.0M)

BA5: System Development & Demonstration/ Engineering, Manufacturing and Development. (Request: \$212.1M/ Conference: \$213.2M)

- Four (4) adds for a total of \$8.3M
- Joint Biological Agent Identification and Diagnostic System (Increment II) (-\$7.2M)



FY 2007 CBDP Procurement Appropriations

CBDP Procurement – FY 2007 Appropriation Marks (+\$12.6M)

<u>Installation Force Protection - JPM Guardian (Request: \$86.2M/Conference: \$90.1M)</u>

- + \$2.2M for WMD-CST (Florida Army National Guard)
- + \$1.8M for WMD-CST (New York Army National Guard)

Decontamination - JPM Decon (Request: \$16.8M/ Conference: \$18.8M)


• + \$2.0M for the M291 Skin Decontamination Kit

Contamination Avoidance - JPM CA (Request: \$236.1M/ Conference: \$242.7M)

 + \$6.6M for M22 Automated Chemical Agent Detector and Alarm for the Army National Guard



FY 2007 CBDP Portfolios (\$M)





FY06 Small Business Contracting Goal

Small Business Goal - 23%

Total Contract Value Year-to-Date \$339.6M

Large Business 68.4% \$232.5M


Small Business 31.6% \$107.1M



DoD Transformation ... Characteristics

Focus in Designing Alternative Architectures:

- Low Unit Cost
- Modularity
- Numbers
- Speed
- Networking
- Sensing
- Innovative Designs
- Mass Customization



Preserve Strategic Advantage: Innovation and the Breadth, Depth and Diversity of the Industrial Base

060927_NDIA_Breakfast UNCLASSIFIED



Major Defense Acquisition Program Chemical/Biological Defense Program Support



Assault Ship

Combat Ship (LCS

CBRN—REQUIREMENTS

CBR Detection
Battle Management
Integrated Early Warning
Collective Protection

Decontamination Individual Protection

OTHERS Bradley, THAAD, CFPI, UAV...





Stryker



Joint Strike Fighter

Infantry Carrier Vehicle Class II Class II Class III Class III

FUTURE COMBAT SYSTEMS

UNCLASSIFIED

060927_NDIA_Breakfast UNCLASSIFIED



Joint CBRN Dismounted Recon System Experiment

HYPOTHESIS

If we had a combination of currently fielded CBRN GOTS and COTS sensors and/or developmental detection and identification equipment carried in a Service survivable platform, then this will eliminate the full spectrum dismounted CBRN Reconnaissance capability gap existing within the Joint Forces and the mounted CBRN reconnaissance, assessment and surveillance capability gap.





OBJECTIVE

- Determine CONOPS, TTPs, and capabilities required for dismounted CBRN reconnaissance for the Infantry BCT's CBRN Recon PLT, SOF Chemical Recon Det, USAF disaster preparedness teams, and USN/USCG maritime interdiction teams.
- Determine which capabilities can be effectively be fielded, trained, and maintained to these teams using COTS solutions.
- Determine what future developmental capabilities are required that can be spiraled in to these teams in the future



Modularity Vision – A Plug & Play CB System








- Multipurpose Interchangeable Detectors
- Common Interface and Communication System



Detector Component In Removable Cartridge











Award Fee Contracts

- OSD(ATL) Guidance is Response to GAO Report
- Guidance to Ensure Award Fees are Tied to Outcomes:
 - Award Fee Provisions Must Clearly Explain How Performance will be Evaluated
 - Fees to be Commensurate with Performance
 - Limitations on Unearned Award Fee Rollovers
 - Establish an Award Fee Community of Practice (COP)
- GAO Report: http://www.gao.gov/new.items/d0666.pdf
- COP at DAU: https://acc.dau.mil/awardandincentivefees



COCO Issues Update

- Personnel Reliability Program Investigations
 - 22 Persons Out of About a Hundred had to Travel Since 2004
 - ECBC will Coordinate Face-to-face Interviews to Coincide with On-site Inspection Visits
 - Subject to Funding, the Certifying Official Will Travel to the COCO for Special Interviews
- Ultradilute Policy
 - Draft Policy in Review for allowing Ultradilute Agents with Significantly Reduced Accountability Requirements



Industry S&T Opportunities

Opportunities	Description	Dates
FY07 Chemical and Biological Defence Initiative Fund	Pending Congressional Language Annual Broad Agency- Announcement	Expected 3d Qtr FY07 posting to FedBizOpps and Grants.gov
FY08 CB Defence Program Science and Technology Program	Broad Agency Announcement – DTRA	Expected 2dQtr FY07

The objective of the <u>CBDIF BAA</u> is to solicit proposals based on Congressional language from degree-granting universities, nonprofit organizations, or commercial concerns to include small businesses, in support of the Chemical and Biological Defense Program (CBDP) to fund chemical and biological defense science and technology projects across a wide-range of military operations. The CBDIF spans both the Physical Science & Technology (S&T) capability areas and the Medical S&T capability areas. Physical S&T capability areas include chemical and biological detection, individual and collective protection, decontamination, and modeling and simulation/battlespace management. Medical S&T capability areas include pre-treatments, therapeutics, and diagnostics. The goal of this initiative is to explore new and innovative ideas to fill identified technology gaps.



Industry JPEO Opportunities

Opportunities	Description	Dates
Joint Modular Decon System	 Capability for platform interior and sensitive item decontamination 	• Expected FY07
Joint Chemical Agent	• FY07 SBIR	• Oct 2006
Detector	• FY08 SBIR	• Oct 2007
Joint Biological Tactical Detection System	 Technology Demonstration of Tactical Bio system capability 	• RFP FY08/09
Joint Expeditionary Collective Protection System (JECP)	• Initial increment - RFP for prime contractor	• 1QFY07
Joint Expeditionary Collective Protection System (JECP)	Second increment - RFP for prime contractor	• 1QFY08
SPAWAR Knowledge Superiority	• BAA	Continual



S&T Medical Upcoming Business Opportunities

Program	Estimated Target BAA Release	Target Funding Year	
Transformational Medical Technology Initiative	1Q/2QFY07 and TBD	FY07 – FY11	
– BAA			
CB Defense Medical S&T Extramural Program	1QFY07	FY08	
- Tech Base - BAA			
Small Business Innovation Research (SBIR)	1QFY07	FY06	
Tech Base			
Chem-Bio Defense Initiative Fund (CBDIF)	3QFY06	FY06	
– BAA			



JPEO Medical Program Business Opportunities

Program	Description	Year	Estimated Contract Value
MITS			
AAS	RFP for Prime Contractor	4QFY06	\$15-25M
INATS	RFP for Prime Contractor	4QFY06	\$20-30M
Medical Radiation Countermeasures	RFP for Prime Contractor	1QFY07	\$40-50M
JVAP – subcontract through DVC			
Plague Vaccine	Multiple clinical site management for Plague vaccine Phase 2 clinical trial	3QFY06	Cost is evaluated separately from technical DVC's
Venezuelan Equine Encephalitis (VEE) Vaccine	NIAID-funded Phase 2 clinical trial	4QFY07	
Recombinant Botulinum (rBot) A/B Vaccine	Clinical site management for rBot vaccine Phase 1B clinical trial	4QFY06	Award based on Best Value

Joint Program Executive Office



Chemical and Biological Defense